Medical Policy

BlueCross BlueShield Kansas
An Independent licensee of the Blue Cross Blue Shield Association

Title: Kresladi

Professional / Institutional
Original Effective Date: July 23, 2026
Latest Review Date:
Current Effective Date: July 23, 2026

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

POLICY AGENT SUMMARY – MEDICAL PRIOR AUTHORIZATION

Indication	Dose
LAD-I	The recommended minimum dose of Kresladi is a single intravenous infusion of 2.8×10^6 CD34+ cells/kg. • For autologous use only. For one-time single-dose intravenous use only.

- *Before mobilization, apheresis, and conditioning are initiated, confirm that autologous hematopoietic stem cell (HSC) transplantation is appropriate for the member.*
- *Consider administering ustekinumab prior to mobilization and apheresis and/or prior to Kresladi infusion.*
- *Kresladi contains human blood cells that are genetically modified with replication-incompetent, self-inactivating lentiviral vector (LVV). Follow universal precautions and local institutional biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.*
- *Vaccination is not recommended during the 6 weeks prior to the start of myeloablative conditioning and until hematologic recovery following treatment with Kresladi.*

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for ONE dose total.
- Renewal: Prior authorization validity may NOT be renewed **§**

§ *Note: Retreatment with marnetegragene autotemcel is considered investigational. While limited retreatment was reported for a single patient in the pivotal clinical study, the available evidence is insufficient to establish the safety and effectiveness of repeat administration. Requests for retreatment will therefore be reviewed on a case-by-case basis, taking into account the totality of clinical circumstances and supporting documentation.*

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 1 dose up to 3.22 $x10^8$ CD34+ cells

III. Initial Approval Criteria [1]

Submission of supporting clinical documentation (including but not limited to medical records, chart notes, lab results, and confirmatory diagnostics) related to the medical necessity criteria is REQUIRED on all requests for authorizations. Records will be reviewed at the time of submission as part of the evaluation of this request. Please provide documentation related to diagnosis, step therapy, and clinical markers (i.e., genetic, and mutational testing) supporting initiation when applicable. Please provide documentation via direct upload through the PA web portal or by fax. Failure to submit the medical records may result in the denial of the request due to inability to establish medical necessity in accordance with policy guidelines.

Prior authorization validity is provided in the following conditions:

Leukocyte Adhesion Deficiency-I (LAD-I) † Φ [1-3]

- Member has a confirmed diagnosis of severe LAD-I defined as all of the following:
  - Neutrophil CD18 expression <2% or CD11a and/or CD11b expression <2% (if neutrophil CD18 expression ≥2%); **AND**
  - Documented biallelic *ITGB2* mutations; **AND**
  - Clinical history consistent with severe LAD-I or a known family history; **AND**
- Member is a candidate for autologous hematopoietic stem cell transplant (HSCT) and has not had prior HSCT; **AND**
- Member does not have a known and available suitable 10/10 human leukocyte antigen (HLA)-matched related donor willing to participate in an allogeneic HSCT; **AND**

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

- Member will undergo mobilization with granulocyte-colony-stimulating factor (G-CSF) and plerixafor prior to apheresis; **AND**
- Member has no active or clinically significant systemic infection and will be monitored for signs and symptoms of infection before and after infusion, with prophylactic antimicrobials administered per institutional guidelines; **AND**
- Member will be monitored for signs and symptoms of veno-occlusive disease including assessment of liver function tests during the first month following infusion; **AND**
- Member has been screened and found negative for human immunodeficiency virus (HIV) in accordance with clinical guidelines prior to mobilization and apheresis *(**Note:** Members who have received Kresladi are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to LVV provirus insertion, resulting in a possible false-positive PCR assay test result for HIV. Therefore, members who have received Kresladi should not be screened for HIV infection using a PCR-based assay.)*; **AND**
- Member will not receive prophylactic HIV anti-retroviral therapy (ART) *(**Note:** Members receiving prophylactic ART should stop therapy for at least one month prior to mobilization, or for the expected duration required for the elimination of the anti-retroviral medications, and until all cycles of apheresis are completed)*; **AND**
- Member will be monitored for lentiviral vector (LVV)-mediated insertional oncogenic hematologic malignancies following treatment as clinically indicated; **AND**
- Member will be monitored and managed according to clinical practice for severe hypersensitivity reactions to dimethyl sulfoxide (DMSO) during and after infusion; **AND**
- Member has not received prior gene therapies used for the treatment of LAD-I including treatment with marnetegragene autotemcel **§**
    - ***§*** *Note: Retreatment with marnetegragene autotemcel is considered investigational. While limited retreatment was reported for a single patient in the pivotal clinical study, the available evidence is insufficient to establish the safety and effectiveness of repeat administration. Requests for retreatment will therefore be reviewed on a case-by-case basis, taking into account the totality of clinical circumstances and supporting documentation.*

† FDA Approved Indication(s); **ǂ** Compendia Recommended Indication(s); **Φ** Orphan Drug

IV. Renewal Criteria [1]

- Duration of authorization has not been exceeded (*refer to Section I*)

Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

CLINICAL RATIONALE

See package insert for FDA preshttps://dailymed.nlm.nih.gov/dailymed/index.cfm

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information

CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.

HCPCS Code(s):

- J3590 – Unclassified biologics
- C9399 – Unclassified drugs or biologicals *(Hospital Outpatient Use Only)*

NDC:

- Kresladi 50 mL infusion bag and metal cassette *(supplied in one or two infusion bags containing a frozen suspension of genetically modified autologous cells enriched for CD34+ cells with each infusion bag containing approximately 30 mL and is individually packed within an overwrap in a metal cassette for protection)*: 83537-0034-xx

REVISIONS	
Posted: 06-23-2026 Effective: 07-23-2026	New medical policy added to the bcbsks.com web site. Policy is maintained by Prime Therapeutics LLC.

REFERENCES

1. Kresladi [package insert]. Cranbury, NJ; Rocket Pharmaceuticals, Inc; March 2026. Accessed April 2026.
2. ClinicalTrials.gov. NCT03812263. A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I. | ClinicalTrials.gov.
3. Booth C, Sevilla J, Almarza E, et al. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2025 May 1;392(17):1698-1709. doi: 10.1056/NEJMoa2407376.

Current Procedural Terminology © American Medical Association. All Rights Reserved.
Blue Cross and Blue Shield Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information